Skip to main content
SpringerLink
Log in

20-Jahres-Ergebnisse einer 5‑jährigen Hormontherapie bei Mammakarzinom

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

The 20-year results of 5‑year hormone therapy in breast cancer

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

  • Klinische Studien
  • Published:
Der Internist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Partridge AH et al (2003) Nonadherence to adjuvant Tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606

    Article  CAS  PubMed  Google Scholar 

  2. EBCTCG, Pan H, Gray R, Brybrooke J et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Eng J Med 377:1836–1846

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie und Geburtshilfe, AGAPLESION Markus Krankenhaus, Wilhelm-Epstein-Str. 4, 60341, Frankfurt am Main, Deutschland

    L. Traub &  M. Thill

  2. Lippetal, Deutschland

    S. Nitschmann

Authors
  1. L. Traub
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Thill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Traub.

Ethics declarations

Interessenkonflikt

M. Thill ist als Berater und Referent der folgenden Firmen tätig: Amgen, AstraZeneca, Celgene, Eisai, Genomic Health, Lilly, Myriad, Neodynamics, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, SurgicEye, Teva. L. Traub und S. Nitschmann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

M. Hallek, Köln

W. Lehmacher, Köln

N. Marx, Aachen

U. Müller-Ladner, Bad Nauheim

H. Wedemeyer, Hannover

M. Wehling, Mannheim

T.R. Weihrauch, Düsseldorf

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Traub, L., Thill, M. & Nitschmann, S. 20-Jahres-Ergebnisse einer 5‑jährigen Hormontherapie bei Mammakarzinom. Internist 59, 410–412 (2018). https://doi.org/10.1007/s00108-018-0398-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-018-0398-1

Search

Navigation